Tirzepatide vs retatrutide: how the two GLP-1 drugs compare

Last updated 2026-07-27

What is the actual difference between tirzepatide and retatrutide?

Tirzepatide is a dual agonist. It activates two gut hormone receptors, GIP and GLP-1, and it's FDA-approved under two brand names: Mounjaro for type 2 diabetes and Zepbound for chronic weight management ^[1][2]. Retatrutide is a triple agonist. It hits GIP, GLP-1, and glucagon receptors. That third target, glucagon, is the theoretical reason it might produce more weight loss, since glucagon receptor activity is linked to increased energy expenditure and fat oxidation in animal models. But retatrutide has no FDA approval for anything. It's made by Eli Lilly and is currently in phase 3 trials for obesity, with trial completion dates that stretch into 2026 and beyond ^[3]. The practical difference for a reader right now: one drug you can get from a licensed pharmacy with a prescription. The other you cannot, unless you're enrolled in a clinical trial. Anything sold online labeled 'retatrutide' outside of a trial is not an FDA-approved or verified drug product.

How much weight loss does tirzepatide produce compared to retatrutide?

In the SURMOUNT-1 trial (NCT04184622), adults with obesity or overweight (without diabetes) lost an average of 20.9% of body weight on the highest tirzepatide dose (15 mg) over 72 weeks, compared to 3.1% on placebo ^[4]. That trial enrolled 2,539 participants and is the primary basis for Zepbound's FDA approval. Retatrutide's phase 2 data, published in the New England Journal of Medicine, showed a mean weight reduction of 24.2% at the highest dose (12 mg) after 48 weeks, versus 2.1% for placebo ^[5]. That's a shorter trial, a smaller sample (about 338 participants across all dose groups), and a phase 2, not phase 3, program. Phase 2 numbers routinely shift once a drug moves to larger, longer phase 3 trials, so treat the 24% figure as promising rather than settled. | Measure | Tirzepatide (SURMOUNT-1) | Retatrutide (phase 2) |

Is tirzepatide FDA-approved? Is retatrutide?

Yes and no. Tirzepatide has two FDA approvals: Mounjaro, approved in May 2022 for type 2 diabetes, and Zepbound, approved in November 2023 for chronic weight management in adults with obesity or overweight plus a weight-related condition ^[1][2]. Retatrutide has no FDA approval of any kind. It exists only in clinical trials run by Eli Lilly. There is no brand name product, no approved label, no dosing instructions from FDA, and no legal commercial supply chain for it as an approved drug ^[3].

How do the side effects compare?

Tirzepatide's side effect profile is well documented across thousands of trial participants. The most common are gastrointestinal: nausea, diarrhea, vomiting, constipation. In SURMOUNT-1, nausea occurred in about 24-33% of participants depending on dose, and these effects were mostly mild to moderate and concentrated during dose escalation ^[4]. Zepbound's FDA label carries a boxed warning about the risk of thyroid C-cell tumors, based on rodent studies with GLP-1 receptor agonists, and the drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) ^[2]. The label also flags risk of pancreatitis, gallbladder problems (including gallstones), severe gastrointestinal disease, and acute kidney injury tied to dehydration from GI side effects. Retatrutide's side effect signal, from the phase 2 trial, looks broadly similar: nausea, diarrhea, constipation, vomiting, and dose-dependent GI symptoms were the main issues reported, along with increases in heart rate at higher doses ^[5]. But phase 2 trials are small and short. A drug's real safety profile, including rare but serious risks, usually only becomes visible after tens of thousands of patients use it for years post-approval. Tirzepatide has that kind of exposure now, through both trials and years of real-world prescribing. Retatrutide does not. Anyone with a personal or family history of MTC or MEN 2 should not use tirzepatide, full stop, and that same caution would reasonably extend to retatrutide given its overlapping mechanism, though retatrutide's label (it has none yet) can't formally say so.

Which drug has more real-world safety data?

Tirzepatide, by a wide margin. Mounjaro has been prescribed since 2022, and Zepbound since late 2023. FDA's adverse event reporting system (FAERS) has accumulated years of post-market data on both. The SURPASS program for diabetes (multiple trials, thousands of participants) and SURMOUNT program for weight (SURMOUNT-1 through SURMOUNT-4) together represent one of the larger evidence bases in recent obesity and diabetes drug development ^[1][4]. Retatrutide has none of that. Its total trial exposure so far is a few hundred to roughly a thousand people across phase 1 and phase 2 studies. Nobody has good long-term data on retatrutide in people with heart disease, kidney disease, or in combination with other common medications, because the trials simply haven't run long enough or enrolled enough people yet.

Can you legally buy retatrutide right now?

Not as an approved drug, no. Retatrutide is not FDA-approved, so there's no pharmacy, compounding or otherwise, that can legally dispense an FDA-approved retatrutide product, because none exists. Some online sellers market 'research chemical' retatrutide, typically labeled 'not for human consumption.' That labeling exists specifically because the seller is not operating under FDA drug manufacturing, testing, or prescribing rules. Buying and injecting a substance sold that way means no verified purity testing, no dosing guidance backed by clinical data, and no prescriber oversight. Compounded tirzepatide is a different, more regulated situation, though still not the same as the brand-name product. During the FDA-declared shortage of tirzepatide, state-licensed compounding pharmacies were permitted to make compounded versions under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act ^[7]. FDA removed tirzepatide from its shortage list in December 2024, which narrows the legal basis for mass compounding going forward, though compounding for individual patient needs under a valid prescription can still occur under specific conditions ^[8]. Compounded tirzepatide is not FDA-approved as a finished product, and it hasn't been through the same trial-based review as Mounjaro or Zepbound. It's a meaningfully different regulatory tier, but it's still built around an approved, evidence-backed molecule, not an unapproved one.

What's the mechanism difference, GIP/GLP-1 vs GIP/GLP-1/glucagon?

Tirzepatide activates two receptors: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both hormones are released naturally from the gut after eating and help regulate insulin secretion, appetite, and gastric emptying ^[1]. Retatrutide adds a third target: the glucagon receptor. Glucagon is usually thought of as insulin's opposite, raising blood sugar by triggering the liver to release glucose. But glucagon receptor activation also appears to increase energy expenditure and support fat breakdown in the liver, at least in preclinical and early clinical work ^[5]. The theory behind triple agonism is that combining appetite suppression (GLP-1), improved insulin sensitivity (GIP), and increased energy burn (glucagon) could produce more weight loss than dual agonism alone. It's a reasonable hypothesis and the phase 2 numbers support it directionally. But adding a third hormonal pathway also adds complexity, more receptors to fine-tune dosing around, and more places for unexpected effects to show up in a larger, longer trial population.

How does dosing work for tirzepatide, and would retatrutide dosing look similar?

Tirzepatide is dosed as a once-weekly subcutaneous injection, starting at 2.5 mg for the first four weeks (a dose not intended for treatment effect, just tolerance), then increasing in 2.5 mg increments every four weeks up to a maintenance dose of 5 mg, 10 mg, or 15 mg, based on response and tolerability ^[1][2]. That slow titration schedule is specifically designed to minimize GI side effects. Retatrutide's phase 2 trial used a similar once-weekly injection structure with doses ranging up to 12 mg, also titrated gradually ^[5]. Whether that becomes the approved dosing schedule, if retatrutide is approved at all, depends on what phase 3 data shows. Doses, titration speed, and maximum tolerated dose commonly shift between phase 2 and the final approved label. For tirzepatide specifically, readers actually starting treatment should look at the Tirz Rx dosage guide for the full titration schedule, and the Tirz Rx dosage calculator for figuring out exact volumes at each step.

Does tirzepatide help with more than weight loss?

Yes. Tirzepatide's original and still primary FDA indication is type 2 diabetes, under the brand Mounjaro. In the SURPASS-2 trial (NCT03987919), tirzepatide reduced HbA1c by up to 2.09% at the 15 mg dose over 40 weeks, compared to 1.73% with semaglutide 1 mg, in a head-to-head comparison ^[9]. That's a genuinely strong glycemic result in a major published trial. Zepbound also picked up an additional FDA approval in December 2024 for moderate to severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trials . Retatrutide has no approved indication for anything yet, in diabetes or otherwise, though Lilly is studying it in both obesity and diabetes populations as part of its trial program ^[3].

Who should not take tirzepatide (or, by extension, be cautious with retatrutide)?

Tirzepatide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, per the FDA label's boxed warning ^[2]. It's also not recommended for anyone with a known serious hypersensitivity to tirzepatide or any of its components. People with a history of pancreatitis should discuss that history carefully with a prescriber before starting, since pancreatitis is a listed warning, more than a side effect footnote, on the Zepbound and Mounjaro labels ^[1][2]. The same goes for gallbladder disease. GLP-1 and GIP receptor agonists are associated with increased gallstone formation, likely tied to rapid weight loss itself rather than a direct drug toxicity, but it's a real, documented risk. Pregnant people, and anyone with severe gastrointestinal disease like gastroparesis, should also avoid tirzepatide absent specific prescriber guidance. Given retatrutide shares the GIP/GLP-1 mechanism plus adds glucagon activity, all of these same caution flags would reasonably apply, even though no formal retatrutide label exists yet to confirm it.

If tirzepatide is available now, how should someone actually start it?

Once a prescriber has confirmed tirzepatide is appropriate, and there's no MTC/MEN2 history, no active pancreatitis, no pregnancy, the practical next steps are about technique, not chemistry. Getting the reconstitution and injection process right matters more for day-to-day comfort and dosing accuracy than most people expect going in. For anyone using compounded tirzepatide that ships as a lyophilized powder, the how to reconstitute Tirz Rx guide walks through mixing it correctly with bacteriostatic water. The Tirz Rx how to inject guide covers technique, and Tirz Rx injection sites covers where on the body to rotate injections to reduce irritation. Most people also want to know how long a typical course runs before reassessing with their prescriber. That's covered in Tirz Rx cycle length, which is worth reading before starting rather than after.

So which one should you actually pursue: tirzepatide or retatrutide?

Tirzepatide, for anyone who wants to start treatment this year. It has FDA approval, a multi-year real-world safety record, two brand-name formulations built specifically for diabetes and obesity, and trial data from thousands of participants across the SURPASS and SURMOUNT programs ^[1][2][4]. That's not a close call. Retatrutide is worth watching, not buying. The phase 2 weight loss numbers are genuinely impressive, and if the phase 3 TRIUMPH program confirms them with an acceptable safety profile, it could become a legitimate next-generation option, possibly by 2027 or later depending on how the trials and FDA review timeline play out ^[3]. Buying unregulated 'research chemical' retatrutide off the internet right now skips every safety check that makes an approved drug trustworthy in the first place. Tirz Rx covers the provider-reviewed route to tirzepatide, including how dosing, titration, and fulfillment through a licensed pharmacy partner actually work, for readers who've already decided tirzepatide, not an unapproved experimental peptide, is the right next step.

Frequently asked questions

Is retatrutide better than tirzepatide for weight loss?

Retatrutide's phase 2 trial showed about 24% weight loss at 48 weeks versus tirzepatide's 20.9% in its phase 3 SURMOUNT-1 trial at 72 weeks. But phase 2 and phase 3 data aren't directly comparable, and retatrutide isn't FDA-approved yet, so there's no confirmed answer until its phase 3 program finishes.

When will retatrutide be FDA approved?

There's no confirmed approval date. Retatrutide's phase 3 obesity trials (the TRIUMPH program) are ongoing, with some studies not expected to complete before 2026 or 2027. FDA review would follow trial completion, so an approval realistically wouldn't happen before then, if the data supports it.

Can I buy retatrutide online legally?

Not as an approved drug. There's no FDA-approved retatrutide product, so no licensed pharmacy can dispense one. Products sold online as 'research chemical' retatrutide are not verified for purity or dosing and aren't legal for human use.

Is tirzepatide the same as Mounjaro and Zepbound?

Yes. Tirzepatide is the active drug molecule. Mounjaro is the FDA-approved brand for type 2 diabetes, approved May 2022. Zepbound is the FDA-approved brand for chronic weight management, approved November 2023. Both are built on the tirzepatide molecule, just with different labeled indications and dosing guidance.

What is the main safety warning for tirzepatide?

Both Mounjaro and Zepbound carry a boxed warning about thyroid C-cell tumor risk, based on rodent studies. The drugs are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, per the FDA label.

Does retatrutide cause the same side effects as tirzepatide?

Broadly, yes. Retatrutide's phase 2 trial reported nausea, diarrhea, vomiting, and constipation as the main side effects, similar to tirzepatide. It also showed dose-dependent heart rate increases. Because trial exposure is much smaller, rarer or longer-term side effects aren't well characterized yet.

Why does retatrutide add a glucagon receptor target?

Glucagon receptor activation is linked to increased energy expenditure and liver fat breakdown in preclinical research. Adding it to GIP and GLP-1 activity is the theory behind why retatrutide might produce more weight loss than dual-agonist drugs like tirzepatide, though this is still being confirmed in larger trials.

Is compounded tirzepatide the same as Zepbound?

No. Compounded tirzepatide is built on the same active molecule but isn't manufactured, tested, or approved as a finished product by the FDA the way Zepbound is. It's produced by state-licensed compounding pharmacies under specific regulatory provisions, and its legal availability has narrowed since FDA removed tirzepatide from its drug shortage list in December 2024.

How long do tirzepatide trials show weight loss lasting?

SURMOUNT-1 followed participants for 72 weeks and showed continued weight loss through that period on the 15 mg dose, averaging 20.9%. Longer-term maintenance data beyond the trial period, and what happens after stopping the drug, is covered in ongoing extension studies and post-market research.

What trial numbers support tirzepatide's approval?

Key trials include SURMOUNT-1 (NCT04184622) for weight loss and SURPASS-2 (NCT03987919) comparing tirzepatide to semaglutide for type 2 diabetes. These are registered on ClinicalTrials.gov and formed part of the evidence FDA reviewed for Mounjaro and Zepbound approvals.

Does tirzepatide help with sleep apnea?

Yes. FDA approved Zepbound in December 2024 for moderate to severe obstructive sleep apnea in adults with obesity, based on results from the SURMOUNT-OSA trial program, making it the first prescription drug approved for that specific use.

Is there a generic version of tirzepatide?

No FDA-approved generic exists yet, since Mounjaro and Zepbound are still under patent protection. Compounded versions from licensed pharmacies exist under separate regulatory rules but are not the same as an FDA-approved generic drug.

Sources

1. FDA, Mounjaro prescribing information: Mounjaro (tirzepatide) FDA approval for type 2 diabetes, mechanism, boxed warning, dosing titration
2. FDA, Zepbound prescribing information: Zepbound (tirzepatide) FDA approval for chronic weight management, contraindications, boxed warning
3. ClinicalTrials.gov, retatrutide TRIUMPH-1 study: Retatrutide phase 3 obesity trial status and estimated completion timeline
4. NEJM, SURMOUNT-1 trial (Jastreboff et al., 2022): Tirzepatide 20.9% mean weight loss at 15 mg over 72 weeks vs 3.1% placebo, SURMOUNT-1 trial design
5. NEJM, retatrutide phase 2 trial (Jastreboff et al., 2023): Retatrutide phase 2 trial showing 24.2% mean weight loss at 12 mg over 48 weeks vs 2.1% placebo
6. ClinicalTrials.gov, retatrutide phase 2 obesity study: Retatrutide phase 2 trial registration, NCT number, participant count
7. FDA, Tirzepatide Drug Shortage update: FDA removal of tirzepatide from the drug shortage list in December 2024
8. NEJM, SURPASS-2 trial (Frias et al., 2021): Tirzepatide HbA1c reduction of up to 2.09% at 15 mg vs 1.73% for semaglutide 1 mg over 40 weeks
9. FDA News Release, Zepbound approval for obstructive sleep apnea: FDA approval of Zepbound in December 2024 for moderate to severe obstructive sleep apnea